159 related articles for article (PubMed ID: 36387246)
1. TMEM158 expression is negatively regulated by AR signaling and associated with favorite survival outcomes in prostate cancers.
Huang J; Liu W; Zhang D; Lin B; Li B
Front Oncol; 2022; 12():1023455. PubMed ID: 36387246
[TBL] [Abstract][Full Text] [Related]
2. Jumonji domain-containing protein RIOX2 is overexpressed and associated with worse survival outcomes in prostate cancers.
He C; Liu W; Sun J; Zhang D; Li B
Front Oncol; 2023; 13():1087082. PubMed ID: 36776320
[TBL] [Abstract][Full Text] [Related]
3. PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite Prognosis in Prostate Cancers.
Yang M; Li JC; Tao C; Wu S; Liu B; Shu Q; Li B; Zhu R
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572596
[TBL] [Abstract][Full Text] [Related]
4. Expressions of glucose transporter genes are diversely attenuated and significantly associated with prostate cancer progression.
Huang H; Song S; Liu W; Ye S; Bao Y; Mirza M; Li B; Huang J; Zhu R; Lian H
Am J Clin Exp Urol; 2023; 11(6):578-593. PubMed ID: 38148933
[TBL] [Abstract][Full Text] [Related]
5. Systematic pan-cancer analysis identifies transmembrane protein 158 as a potential therapeutic, prognostic and immunological biomarker.
Li J; Hou H; Sun J; Ding Z; Xu Y; Li G
Funct Integr Genomics; 2023 Mar; 23(2):105. PubMed ID: 36977915
[TBL] [Abstract][Full Text] [Related]
6. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway.
Fu Y; Yao N; Ding D; Zhang X; Liu H; Ma L; Shi W; Zhu C; Tang L
J Cell Physiol; 2020 Mar; 235(3):2761-2775. PubMed ID: 31531884
[TBL] [Abstract][Full Text] [Related]
7. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of TMEM158 contributes to ovarian carcinogenesis.
Cheng Z; Guo J; Chen L; Luo N; Yang W; Qu X
J Exp Clin Cancer Res; 2015 Aug; 34(1):75. PubMed ID: 26239324
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of multiple glycolytic enzyme genes is significantly associated with disease progression and survival outcomes in prostate cancers.
Xu H; Liu W; He C; Mirza M; Li B
Am J Clin Exp Urol; 2023; 11(6):530-541. PubMed ID: 38148940
[TBL] [Abstract][Full Text] [Related]
10. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
11. TMEM158 Regulates the Canonical and Non-Canonical Pathways of TGF-β to Mediate EMT in Triple-Negative Breast Cancer.
Tong J; Li H; Hu Y; Zhao Z; Li M
J Cancer; 2022; 13(8):2694-2704. PubMed ID: 35711843
[TBL] [Abstract][Full Text] [Related]
12. Silencing of TMEM158 Inhibits Tumorigenesis and Multidrug Resistance in Colorectal Cancer.
Liu L; Zhang J; Li S; Yin L; Tai J
Nutr Cancer; 2020; 72(4):662-671. PubMed ID: 31389251
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
14. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
15. Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
Nanda JS; Awadallah WN; Kohrt SE; Popovics P; Cates JMM; Mirosevich J; Clark PE; Giannico GA; Grabowska MM
Prostate; 2020 Sep; 80(13):1058-1070. PubMed ID: 32692871
[TBL] [Abstract][Full Text] [Related]
16. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
17. TMEM158 May Serve as a Diagnostic Biomarker for Anaplastic Thyroid Carcinoma: An Integrated Bioinformatic Analysis.
Li HN; Du YY; Xu T; Zhang R; Wang G; Lv ZT; Li XR
Curr Med Sci; 2020 Dec; 40(6):1137-1147. PubMed ID: 33428142
[TBL] [Abstract][Full Text] [Related]
18. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.
Bluemn EG; Spencer ES; Mecham B; Gordon RR; Coleman I; Lewinshtein D; Mostaghel E; Zhang X; Annis J; Grandori C; Porter C; Nelson PS
Mol Cancer Res; 2013 Jun; 11(6):568-78. PubMed ID: 23493267
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
20. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
